Clinical Trial · NCT06103838

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

Overview

Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective: To find out if the radiotracer 18F-fluciclovine (a substance injected into the blood during imaging scans) is better at detecting MM than the one (18F-FDG) currently used for this purpose.

Sponsor

National Cancer Institute

Phase

Phase 2

Contacts

NCI Medical Oncology Referral Office

ncimo_referrals@nih.gov

(888) 624-1937

Elizabeth M Hill, M.D. (Principal Investigator)

elizabeth.hill@nih.gov

(240) 889-5377

ClinicalTrials.gov

NCT06103838

Drug / Compound

Isotope(s):

Target(s):